Gallbladder figures in the product information
The labels draw on two kinds of evidence: the shorter placebo-controlled glucose trials (Trial 1 and Trial 6 in the US label, PIONEER 1 and PIONEER 8 in Canada) and the four-year cardiovascular outcome trial, which the US label calls Trial 7 and Europe and Canada call SOUL [1][2][3].
| Source and study | Event | Rybelsus® | Placebo |
|---|---|---|---|
| US PI 5.8, glucose trials [1] | Gallstones | 1% on 7 mg | not given |
| Canadian PM Table 3, PIONEER 1 and 8 [3] | Gallstones | 7 mg 1.1%; 14 mg 0% | 0% |
| US PI 5.8, Trial 7 (SOUL), about 4 years [1] | Gallstones | 1.1% on 14 mg | 0.9% |
| US PI 5.8, Trial 7 (SOUL) [1] | Gallbladder inflammation (cholecystitis) | 1.1% on 14 mg | 0.7% |
| EU SmPC 4.8 [2] | Gallstones | “Uncommon” (up to 1 in 100) | — |
Reading SOUL in proportion
SOUL randomised 9,650 adults aged 50 or older with type 2 diabetes and heart disease, chronic kidney disease or both to 14 mg or placebo, on top of usual care, for a median of about 49.5 months [1]. Per 1,000 people, that is roughly 11 with gallstones on the tablet against 9 on placebo, and 11 against 7 for inflammation: a few people per thousand over four years, in the same direction as the warning.
Two cautions apply. Safety collection in SOUL was limited to serious events, events that led to stopping and events of special interest [1]. And the 1% figure for 7 mg in the shorter trials has no placebo comparison in the US label; Canada fills that gap with 0% on placebo, but also 0% on 14 mg [3], which suggests how few cases sit behind these percentages.
What larger analyses show
A 2022 meta-analysis of 76 randomised trials with 103,371 people found GLP-1 medicines linked to a 37% higher relative risk of gallbladder or bile-duct disease, including gallstones and gallbladder inflammation [4]. The link was stronger at higher doses, with longer treatment and in weight-loss trials than in diabetes trials [4]. A 2025 meta-analysis of 55 placebo-controlled trials estimated about 2 extra gallstone cases per 1,000 people [5]. Both pool many medicines, so they describe the class rather than Rybelsus® alone.
Among 2,398 FDA reports for semaglutide tablets, acute gallbladder inflammation was one of the strongest signals, with 18 reports, and bile-duct stones appeared in 6 [6]. Reports show what stands out, not how often it happens or whether the tablet caused it [6].
Why gallstones may form
- From the label: none of the three documents gives a mechanism; they list gallbladder disease as a warning and ask for gallbladder studies when it is suspected [1][2][3].
- Proposed, not measured for Rybelsus®: NIH explains that fasting or fast weight loss makes the liver release more cholesterol into bile and can stop the gallbladder emptying fully [8]. The meta-analysis pattern, with more risk in weight-loss trials and at higher doses, fits this idea but does not prove it [4].
- Background risk: MedlinePlus lists diabetes, excess weight, female sex, age over 40, a family history, some ethnic backgrounds and birth control pills as factors that make gallstones more likely [9]. Many people taking Rybelsus® already carry several of these.
How a gallbladder attack feels
NIH describes a gallbladder attack as pain in the upper right abdomen that can last several hours, often after a heavy meal and often in the evening or at night [7]. MedlinePlus adds that the pain may be constant or cramping, sharp or dull, sometimes with fever, nausea, vomiting or yellowing of the skin [9]. Most gallstones cause no symptoms at all; NIH calls these silent gallstones and says they do not need treatment [7].
The Rybelsus® Medication Guide lists upper stomach pain, yellow skin or eyes, fever and clay-coloured stools as possible signs, and asks you to tell your provider right away [1]. Similar pain can come from pancreatitis, ulcers, reflux or appendicitis, which is why NIH says it needs a doctor [7].
What you can do
Know the attack symptoms and the signs that need same-day care. NIH advises against crash diets and repeated cycles of losing and regaining weight, both of which can raise gallstone risk [8]. If your care plan includes weight loss, ask your prescriber how fast is reasonable for you.
If gallstones are suspected, the US label calls for gallbladder studies and clinical follow-up [1]. Should surgery be needed, tell the surgical and anaesthesia team you take Rybelsus®, because it slows stomach emptying and food in the lungs has been reported rarely during anaesthesia or deep sedation [1].
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that does not go away, sometimes through to the back | Stop Rybelsus® and call your provider right away (possible pancreatitis) | Emergency | Rybelsus® Medication Guide [1] |
| Abdominal pain lasting several hours, with fever or chills, nausea or vomiting | A doctor right away | Emergency | NIDDK [7] |
| Yellow skin or eyes, tea-coloured urine or light-coloured stools | A doctor right away | Today | NIDDK [7]; Rybelsus® Medication Guide [1] |
| Upper stomach pain with fever, or clay-coloured stools | Your provider right away | Today | Rybelsus® Medication Guide [1] |
| Gallstones found on a scan without symptoms, or planned gallbladder surgery | Your prescriber and the surgical team | At your next appointment | NIDDK [7]; Rybelsus® PI 5.9 [1] |
